MMP2 and cancer: Therefore, a MMP-2/GHS dual-responsive liposome-based nanovesicle (ENP919@5-FU) was constructed, mainly consisting of MMP-2-responsive mPEG-GG-PPA, containing S-S linoleic acid-embellished NLG919 and 5-FU anti-cancer drug, for circulating chemoimmunotherapy amplification modes to effectively treat PDAC by reversing chemotherapy-mediated inhibition of the TIM.